Dummer R - Search Results

1

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. Krieg C, et al. Among authors: dummer r. Nat Med. 2018 Feb;24(2):144-153. doi: 10.1038/nm.4466. Epub 2018 Jan 8. Nat Med. 2018. PMID: 29309059 Free article.

2

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Nestle FO, et al. Among authors: dummer r. Nat Med. 1998 Mar;4(3):328-32. doi: 10.1038/nm0398-328. Nat Med. 1998. PMID: 9500607 Clinical Trial.

3

Sorafenib in melanoma.

Mangana J, Levesque MP, Karpova MB, Dummer R. Mangana J, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2012 Apr;21(4):557-68. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. Expert Opin Investig Drugs. 2012. PMID: 22394203 Review.

4

Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy.

Rozati S, Naef L, Levesque MP, French LE, Dummer R. Rozati S, et al. Among authors: dummer r. J Immunother. 2013 Jan;36(1):52-6. doi: 10.1097/CJI.0b013e31827809c7. J Immunother. 2013. PMID: 23211621

5

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Das Thakur M, et al. Among authors: dummer r. Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9. Nature. 2013. PMID: 23302800 Free PMC article.

6

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Raaijmakers MI, et al. Among authors: dummer r. Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162. Immunotherapy. 2013. PMID: 23413908 Review.

7

Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MIG, Hemmi S, Dummer R, Levesque MP. Widmer DS, et al. Among authors: dummer r. J Invest Dermatol. 2013 Oct;133(10):2436-2443. doi: 10.1038/jid.2013.115. Epub 2013 Mar 8. J Invest Dermatol. 2013. PMID: 23474946 Free article.

8

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Guenova E, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2014 Apr;23(4):457-67. doi: 10.1517/13543784.2014.876407. Epub 2014 Jan 8. Expert Opin Investig Drugs. 2014. PMID: 24397291 Review.

9

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. Dummer R, et al. J Invest Dermatol. 2014 May;134(5):1200-1201. doi: 10.1038/jid.2014.62. J Invest Dermatol. 2014. PMID: 24732335 Free article.

10

Basal cell carcinomas in a tertiary referral centre: a systematic analysis.

Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Dreier J, et al. Among authors: dummer r. Br J Dermatol. 2014 Nov;171(5):1066-72. doi: 10.1111/bjd.13217. Epub 2014 Oct 20. Br J Dermatol. 2014. PMID: 24974741

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

994 results

Search Page